Evidence map›Paper›PMID 37138292›Full record

ReviewJournal of biomedical science2023

Efficacy analysis and research progress of complementary and alternative medicines in the adjuvant treatment of COVID-19.

Jaung-Geng Lin, Guan-Jhong Huang, Yi-Chang Su

Registry-linked trialOpen access · diamondAbstract readReview
In one paragraph

Review in Journal of biomedical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07583992 (Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07583992 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia

TypeinterventionalSponsorNational Research Institute of Chinese Medicine, Ministry of Health and WelfareRan2026 to 2027Enrolled150ConditionsMild to Moderate, Community-Acquired Pneumonia (CAP), Antibiotic Therapy, IntravenousArmsNRICM102, Placebo, Intravenous Antibiotic
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Dual regulation of antiviral IFN response byJournal of pharmaceutical analysis · 2026
    Article
  2. Bioactive Compounds ofInternational journal of molecular sciences · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Jaung-Geng LinSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung, 40402, Taiwan.
Guan-Jhong Huang *Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, No.91, Hsueh-Shih Road, Taichung, 40402, Taiwan. gjhuang@mail.cmu.edu.tw.ORCID http://orcid.org/0000-0002-9822-3485
Yi-Chang Su *National Research Institute of Chinese Medicine, Ministry of Health and Welfare, No.155-1, Section 2, Linong Street, Beitou District, Taipei, 11221, Taiwan.
Asia University · TWChina Medical University · TWNational Research Institute of Chinese Medicine · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has impacted human lifestyles around the world, causing huge distress in terms of public health systems, emergency response capacity and economic development. The causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with respiratory involvement, cardiovascular-related diseases, and ultimately causes multiple organ failure and death in severely affected individuals. Thus, effective prevention or early treatment of COVID-19 is critical. An effective vaccine offers a way out of the pandemic for governments, the scientific community and people worldwide, but we still lack effective drug therapies, including treatments for the prevention and treatment of COVID-19. This had led to a high global demand for many complementary and alternative medicines (CAMs). Moreover, many healthcare providers are now requesting information about CAMs that prevent, relieve, or treat the symptoms of COVID-19 and even alleviate vaccine-related side effects. Experts and scholars must therefore become familiar with the use of CAMs in COVID-19, current research directions and effectiveness of CAMs for COVID-19. This narrative review updates the current status and research worldwide on the use of CAMs for COVID-19. The review provides reliable evidence on theoretical viewpoints and therapeutic efficacies of CAM combinations, and evidence in support of the therapeutic strategy of Taiwan Chingguan Erhau (NRICM102) against moderate-to-severe novel coronavirus infectious disease in Taiwan.

Indexed as

COVID-19HumansSARS-CoV-2TaiwanAnti-inflammationAntivirusComplementary and alternative medicinesNRICM102SARS-CoV-2Viral infection

Identifiers

PMID37138292
PMCPMC10155165
OpenAlexW4367843930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.